mRNA future

welcome to today's talk Tuesday the 11th of June now the MRNA vaccines are expanding around the world there's multiple plants that have been built to produce them so let's have a look at where we are at globally all of the issues that have been raised the concerns the adverse reactions um don't really seem to have been taken into full cognizance and um that they're plowing ahead let me give some examples here let's start off with this one this is from madna itself now this is the website it's from I've put the references in of course as always uh from madna madna receives us FDA approval for RSV vaccine now what this vaccine is is it's uh was 31st May 2024 madna today announced that the US Food and Drug Administration FDA has approved it so it's a it's called that that's the name of the vaccine they're using there or the the genetic uh genetic sequence that they're giving and as we see it's an mRNA vaccine messenger ribonucleic acid vaccine now now approved as a as a second vaccine now when you give an intramuscular injection into the deltoid the very very small lipid nanop particles some of them are going to stay there but others are going to go back into the systemic circulation they'll drain in the veins eventually draining into the venne Caba which will go back into the right side of the heart that will pump the blood to the lungs the lungs will the blood will come back from the lungs in the pulmonary veins to the left side of the heart in the aorta the left ventricle will pump the blood into the aort and the aort will take it everywhere apart from the the lung tissue so it'll take it to your ears it'll take it to your nose it'll take the blood to your toes it'll take it to your myocardium it'll take it to your brain it'll take it to your testes or ovaries this is the concern the systemic distribution but it's now been approved by the uh FDA for respiratory sensial virus common virus to protect adults age 60 years and older from lower respiratory tract dis disease caused by respir respir sensial Virus Infection um some people might think that the risk of the vaccine is greater than that caused by RSV in older people this is what the uh press release says the approval was granted under a breakthrough therapy designation so a breakthrough therapy designation and marks the second approved mRNA product for madna of course after the um the covid vaccines chief executive of madna the FDA approval of our second product Builds on the strength and versatility of our mRNA platform and this is indeed true the MRNA platform is remarkably versatile you can string together any sequence you want to make pretty well anything you want and inject it into the human body but another main concern I have is as well as the systemic distribution is this is going to go to all of the cells potentially in the body so let let's imagine that this for example is a cell lining the vascular endothelium of the uh myocardium the blood that's going through The myocardium these squamous cells and then Along Comes the uh lipid nanop particle here that sends in the r into the cell the cell's genetic apparatus will then produce the antigen now when you give a mRNA vaccine you could produce a little bit of antigen or you could produce one heck of a lot of antigen um as far as I know the dose of RNA that you give is not that closely well it doesn't determine the the amount of antigen you produce so you could produce a little bit or you could produce a lot and to me this goes against one of the completely fundamental axioms of giving drugs you give the right dose of the right drug to the right patient at the right time via the right route how do you know the dose because you don't know how much antigen the body is going to produce anyway going back to the diagram the the cells here will then produce the antigen whatever it is now if that's in your arm and you get some white blood cells coming along say some cytotoxic tea cells coming along and these cytotoxic cytotoxic tea cells if they they will recognize this antigen as foreign and they'll start beating it up and probably could eventually kill the whole cell actually um now if that's in your arm you get a sore arm if it's in your um myocardium you'll get inflammation in your myocardium so the spike protein was particularly uh pathogenic very strange that the spike protein was was was chosen very very strange in my view um but any antigen that goes onto the surface of the cells will be recognized by the immune system the inflammatory reaction will be there the immune system will attack these cells thinking that these cells are virally infected and kill these cells and this concern as far as I know hasn't been addressed and yet the program um plows on um a pace so that is uh that's my concern there the systemic distribution and um the production of unknown amounts or indeterminate amounts of um antigen and the reaction of the immune cell to the antigen expressed by the body cells of course this might not be a cell these cells might not be in The myocardium um they might be in the testes or the ovaries you see why I'm concerned anyway Let's uh go on that was that announcement a little bit more on that um Mna expects to have this uh irsv vaccine available for eligible populations in the United States by 2024 2025 respiratory virus season which of course is next winter madna has filed Mr approval with regulatory in Regulators in multiple markets around the world so I don't know but I mean we can assume that this includes the United Kingdom I think I think we can assume it includes Australia Canada New Zealand in fact I assume it includes anyone who can pay um I will not be getting one let's move on to another uh area here uh this is from uh clinical trials Arena now here's the uh here's the announcement on this one check it out this is not me making it up all the information is there for your uh perusal now madna races ahead in flu and covid-19 combo vaccine race with phase three win um win okay called it a win uh now this is called madna injection Mr again messenger ribonucleic acid so as well as the RSV we're now getting this influenza one changing to mRNA now of course we do have existing influenza vaccines but they want to replace it with these new genetic sequence vaccines let's see seems to be the way uh progress is being um facilitated now this Mr Mr uh 1083 uh comprises a seasonal influenza vaccine so it contains an influenza vaccine and this is the the MRNA uh 1010 is the influenza mRNA vaccine so again the RNA will code for a sequence and the body's own cells will produce it expressing it on their surfaces and of course another concern is um and we haven't heard this fully addressed is uh normally M uh normally it's RN uh sorry DNA deoxy ribonucleic acid makes RNA makes a protein that's called the central dogma and uh DNA converted into RNA that will be called a transcription and this RNA into protein will be called translation if RNA takes the information back into DNA that would be called reverse transcription and we know that there are enzymes in the body called reverse transcriptase let's hope that doesn't happen and the next so so it contains this is this is the influenza vaccine here and this is the new uh what are they calling it next Generation covid-19 vaccine Prospect and that's the new uh covid vaccine so it's a combo of the influenza RNA and the uh Co RNA so this would be giving two RNA vaccines to the same person in the syringe same syringe in the same injection site now this is not me making this up honestly look on these references I've given you and check it out for uh yourself um it is all there I know you might be struggling with credulity and belief but I'm just reporting what is on these references that I'm giving you madna announces positive data from a phase three trial from its Mr vaccine candidate uh so now in phase three trial so these phase three trials that's the trial there it does seem to be ongoing mad say statistically significant higher immune response compared to a existing vaccines on the market the trial met its preliminary end points as released on the 10th of June press release immune response re SE across three influenza strain so it looks like this is coding for three influenza strains H1N1 H3N2 these are different influenza strains and B Victoria so three different types of influen s Tri veent thing so presumably it contains three types of RNA I don't know presumably it does and the covid spike protein assuming they're still using the spike protein RNA Allin one injection although madna is not published the full data from the phase 3 trials yet it plans to present the results in a more detail an upcoming medical conference okay upcoming medical conference in addition to submission for publication the company said it will engage with Regulators on the next step so looks like it's uh coming to a regulator near you right now it's not just this there's other RN vaccines in the pipeline let me just give you this is on this this is from this um information here madna advances multiple vaccine programs in late stage clinical trials from their press release of the 27th of March 2024 so cyto megala virus uh is an EP pivotal phase 3 trial evaluating this is the MRNA cyto megala virus so again presumably this codes for the cyto megala virus uh some of the cyto megala virus antigens epitopes um cegala virus very common doesn't cause a problem most of the time but can to be fair cause problems to Children if they get it from their mother epin bar virus um now this is the virus that causes infective uh moncle mononucleosis the um um GL fever which can be a very nasty infection in adults but of course virtually everyone's been exposed to it probably 95% of the population have got antibodies to it already um The randomized Observer blind Placebo controlled study is fully enrolled so it looks like this uh EBV Epstein by virus trial is ready to rock and roll herp simply another mRNA vaccine phase one two trials at the moment varilla zoster this would be for shingles primarily I guess um mRNA 1468 as initial data available from a phase one two drout Norv virus vad that you get watery diarrhea for a few days another mRNA uh vaccine being uh actively uh developed so as far as I know British government's got a deal with madna last time I checked just for a billion pounds I think I think we've agreed to buy these vaccines over the next 10 years same in Australia huge new mRNA plants being built same in Canada um mRNA looks like the future doesn't it needless to say will not be enrolling for any of these trials I will not be accepting any of these vaccines but that's what's happening they are being developed on a totally huge scale and uh fda's already approved one extra one Regulators around the world are being approached it's it's quite unbelievable but it's going ahead just think of all the people that we've interviewed just on this channel with with vaccine injuries and yet this is all going ahead in my view without adequately addressing safety concerns quite incredible but The Regulators are there to protect us hopefully they'll do that I mean they are largely funded by the pharmaceutical industry but sure that won't influence their decision- making at all nothing else to say really I mean that I'm just giving you this information um yeah that's it interesting future ahead thank you for watching

Channel: Dr. John Campbell

Views: 786,842

Keywords: physiology, nursing, NCLEX, health, disease, biology, medicine, nurse education, medical education, pathophysiology, campbell, human biology, human body

Id: tFzTTuuzfH0

Length: 17min 10sec (1030 seconds)

Published: Tue Jun 11 2024